GLPwatch
In overweight or obesity without diabetes, weekly semaglutide vs. daily liraglutide increased weight loss at 68 wk.
Ann Intern Med · 2022
Last updated 2026-05-28In a study of 68 weeks, adults with overweight or obesity but without diabetes lost more weight on a weekly dose of semaglutide (15.3%) compared to a daily dose of liraglutide (6.7%). The study included 338 participants.
AI summary of the abstract below.
| Journal | Ann Intern Med, 2022 |
|---|---|
| Citations | 6 |
| Relative citation ratio | 0.43 |
| NIH percentile | 26 |
| Molecules | semaglutide, liraglutide |
| Conditions studied | Obesity |
Abstract
Rubino DM, Greenway FL, Khalid U, et al. JAMA. 2022;327:138-50. 35015037.
Verbatim abstract via PubMed 35500264 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.